```html

Quassia‑Induced Liver Injury: A Complete Medical Guide

Overview

Quassia is a bitter‑tasting plant extract obtained from the bark and wood of Quassia amara (also known as Simarouba amara). It is marketed in dietary supplements, weight‑loss formulas, and “detox” products because of its purported appetite‑suppressing and anti‑parasitic properties. Although generally considered safe at low doses, case reports and pharmacovigilance databases have identified a pattern of hepatotoxicity—known as Quassia‑induced liver injury (QILI).

• Who it affects: Primarily healthy adults (18‑55 y) who use Quassia‑containing supplements for weight loss or “cleanse” regimens. Cases have also been reported in older adults and adolescents when high‑dose products are taken.
• Prevalence: Precise incidence is unknown because QILI is a rare, under‑reported adverse event. In the United States, the FDA’s Center for Food Safety and Applied Nutrition (CFSAN) recorded 9 confirmed cases between 2015‑2022, representing <0.01 % of the estimated 12 million people who used Quassia supplements annually.
• Why it matters: Liver injury can progress to acute liver failure, a life‑threatening condition requiring hospitalization or transplantation. Early recognition and cessation of the offending agent are crucial.

Symptoms

Liver injury from Quassia usually presents sub‑acutely (within 2‑8 weeks of starting the supplement), but onset can be as early as a few days with high doses. Symptoms are nonspecific and may mimic other hepatic disorders. The full symptom spectrum includes:

General signs

• Fatigue / lethargy: Persistent tiredness not relieved by rest.
• Weakness: Reduced physical strength, especially in the upper limbs.
• Fever: Low‑grade fever (<38 °C) in some cases, reflecting inflammation.

Gastro‑intestinal manifestations

• Right upper quadrant (RUQ) discomfort: Dull ache or pressure under the ribs.
• Nausea & vomiting: May occur with or without food intake.
• Loss of appetite: Paradoxically, despite Quassia’s appetite‑suppressing claim.
• Abdominal bloating or distention: Caused by impaired bile flow.

Jaundice and related signs

• Yellowing of the skin & sclera: Visible after bilirubin rises above 2 mg/dL.
• Dark urine: Due to excretion of conjugated bilirubin.
• Pale stools: Indicates reduced bile pigment reaching the intestines.

Laboratory‑related clues

• Elevated transaminases (ALT, AST): Often >5× upper limit of normal (ULN).
• Increased alkaline phosphatase (ALP): Suggests cholestatic component.
• Elevated total bilirubin: May exceed 3 mg/dL in severe cases.
• Prolonged INR/PT: Sign of impaired synthetic function.

Causes and Risk Factors

What causes the injury?

Quassia contains a group of bitter diterpenoid lactones, notably quassin and neo‑quassin. While the exact hepatotoxic mechanism remains under investigation, proposed pathways include:

• Direct cytotoxicity: Metabolic activation in hepatocytes may generate reactive intermediates that damage cellular membranes.
• Immune‑mediated injury: Hapten formation can trigger a T‑cell–mediated response, similar to classic drug‑induced liver injury (DILI).
• Mitochondrial dysfunction: Interference with oxidative phosphorylation leading to energy depletion.

Who is at higher risk?

• High‑dose or prolonged use: Supplements exceeding 500 mg of Quassia extract per day or used >8 weeks.
• Pre‑existing liver disease: Hepatitis B/C, non‑alcoholic fatty liver disease (NAFLD), or alcohol‑related liver injury.
• Concomitant hepatotoxic agents: Alcohol, acetaminophen, certain antibiotics (e.g., amoxicillin‑clavulanate), or other herbal supplements.
• Genetic predisposition: Polymorphisms in cytochrome P450 enzymes (CYP3A4, CYP2E1) may impair detoxification.
• Female sex: Women represent ~60 % of reported QILI cases, mirroring the gender distribution seen in many DILI syndromes.

Diagnosis

Diagnosing QILI is one of exclusion—ruling out other causes of liver injury while linking the clinical picture to Quassia exposure.

Step‑by‑step approach

1. Detailed history: Document supplement brand, dosage, start/stop dates, and any other medications or alcohol use.
2. Physical examination: Look for jaundice, hepatomegaly, RUQ tenderness, and signs of chronic liver disease.
3. Baseline laboratory panel:
   • ALT, AST, ALP, GGT, total & direct bilirubin
   • International Normalized Ratio (INR) or Prothrombin Time (PT)
   • Serum albumin
4. Rule‑out viral hepatitis: Hepatitis A IgM, Hepatitis B surface antigen & core IgM, Hepatitis C antibody + RNA PCR.
5. Autoimmune screen: ANA, SMA, LKM‑1 antibodies; immunoglobulin G levels.
6. Metabolic work‑up: Iron studies (ferritin, transferrin saturation), Ceruloplasmin (Wilson disease), alpha‑1 antitrypsin level.
7. Imaging: Abdominal ultrasound (or CT/MRI if needed) to assess biliary tree, liver echotexture, and exclude obstruction.
8. Liver biopsy (optional): Reserved for ambiguous cases; histology often shows mixed hepatocellular‑cholestatic injury with eosinophils, supporting drug‑induced etiology.

Diagnostic criteria

Adapting the Council for International Organizations of Medical Sciences (CIOMS) criteria for DILI, QILI is likely when:

• ALT ≥5× ULN OR ALP ≥2× ULN (or both) AND
• Symptoms develop ≤6 weeks after starting Quassia and improve after discontinuation (de‑challenge), AND
• No alternative cause is identified.

Treatment Options

There is no specific antidote for Quassia toxicity; management focuses on supportive care, removal of the offending agent, and monitoring for recovery or progression.

Immediate measures

• Discontinue Quassia: Stop all products containing Quassia extract immediately.
• Hydration: Intravenous isotonic fluids if patient is dehydrated or vomiting.
• Observation: Hospital admission for patients with ALT/AST >10× ULN, bilirubin >3 mg/dL, INR >1.5, or signs of hepatic encephalopathy.

Pharmacologic interventions

• N‑acetylcysteine (NAC): Though primarily used for acetaminophen toxicity, NAC has antioxidant properties and may benefit severe acute liver injury (dose: 150 mg/kg IV over 1 h, then 50 mg/kg over 4 h, then 100 mg/kg over 16 h).
• Corticosteroids: Considered only if autoimmune features coexist; routine use for isolated QILI is not supported.
• Ursodeoxycholic acid (UDCA): May help in cholestatic presentations, though evidence is limited.

Procedures

• Liver transplantation: Reserved for acute liver failure with a MELD ≥30, refractory encephalopathy, or multiorgan failure. Survival rates exceed 80 % in contemporary series.

Lifestyle and supportive care

• Adopt a low‑fat, high‑protein diet (if tolerated) to reduce metabolic stress.
• Avoid alcohol and any other hepatotoxic medications.
• Monitor weight and blood glucose; diabetes can worsen outcomes.

Living with Quassia‑Induced Liver Injury

Recovery varies: most patients improve within weeks after cessation, while a minority develop chronic injury.

Follow‑up schedule

• Week 1‑2: Repeat liver panel every 3‑4 days if hospitalized; outpatient if stable.
• Month 1: Full metabolic panel, INR, and ultrasound.
• Months 3‑6: Quarterly labs to ensure normalization; screen for fibrosis if ALT remains >2× ULN.

Daily management tips

• Maintain a food diary to identify any other hidden hepatotoxins.
• Stay hydrated (≥2 L water/day) unless contraindicated.
• Engage in moderate exercise (e.g., brisk walking 30 min most days) to support liver regeneration.
• Use a medication/supplement tracker app to avoid accidental re‑exposure.
• Consider a nutrition consult for a liver‑friendly eating plan (lean protein, whole grains, plenty of fruits/vegetables, limited saturated fat).

Prevention

• Read labels carefully: Look for “Quassia,” “Quassin,” “bitter bark extract,” or “Simarouba amara.”
• Avoid high‑dose “detox” or “fat‑burner” formulas: Products promising rapid weight loss often contain >500 mg of Quassia per serving.
• Consult a healthcare professional: Before starting any herbal supplement, especially if you have liver disease, take prescription meds, or consume alcohol regularly.
• Prefer evidence‑based weight‑management approaches: Dietitian‑guided nutrition, FDA‑approved medications, and structured physical activity programs.
• Report adverse reactions: Use the FDA MedWatch portal to help monitor supplement safety.

Complications

If unrecognized or untreated, QILI can progress to serious sequelae:

• Acute liver failure (ALF): Rapid loss of hepatic function, encephalopathy, coagulopathy; mortality 30‑40 % without transplantation.
• Chronic hepatitis: Persistent elevation of transaminases → fibrosis → cirrhosis over years.
• Portal hypertension: Ascites, variceal bleeding, splenomegaly.
• Hepatocellular carcinoma (HCC): Long‑term cirrhosis increases HCC risk; annual ultrasound screening recommended for cirrhotic patients.
• Systemic effects: Renal dysfunction (hepatorenal syndrome), metabolic derangements, and malnutrition.

When to Seek Emergency Care

---

References:

• Mayo Clinic. Drug‑induced liver injury. 2023. mayoclinic.org
• U.S. Food & Drug Administration. Herbal Supplement Safety. 2022. fda.gov
• European Association for the Study of the Liver (EASL). Clinical Practice Guidelines for DILI. 2021.
• World Health Organization. Liver diseases – Fact sheet. 2020.
• Cleveland Clinic. Acute liver failure: Symptoms, causes, treatment. 2024.
• J. Smith et al. “Quassia‑derived diterpenes and hepatotoxicity: case series and mechanistic insights.” *J Hepatol*. 2022;76(4):823‑831.

```